3 magg 2016 anni - FDA convened a joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee to discuss results from assessments of the extended-release and long- acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategies (REMS)
Aggiunto al nastro di tempo:
Data:
3 magg 2016 anni
Adesso
~ 8 years ago
